Sharlene Adams

Address:

22750 Dixie Riv Rd, Caldwell, ID 83607

Phone:

(208)4542882

VIN:

1FTWW31P57EA05164

Make:

FORD

Model:

F-350 SUPER DUTY

Year:

2007

US Patent:

6432409, Aug 13, 2002

Filed:

Sep 14, 1999

Appl. No.:

09/396813

Inventors:

Robert E. Humphreys - Acton MA
Sharlene Adams - Watertown MA
Minzhen Xu - Northborough MA

Assignee:

Antigen Express, Inc. - Worcester MA

International Classification:

A61K 3900

US Classification:

4241921, 4241841, 4241851, 530328

Abstract:

The present invention provides an MHC class II antigen presentation enhancing hybrid polypeptide. The hybrid has an N-terminus comprising the mammalian Ii key peptide LRMKLPKPPKPVSKMR (SEQ ID NO: 1) and modifications thereof which retain antigen presentation enhancing activity, a C-terminus comprising an antigenic epitope in the form of a polypeptide or peptidomimetic structure which binds to the antigenic peptide binding site of an MHC class II molecule, and an intervening chemical structure covalently linking the N-terminal and C-terminal components.

US Patent:

6770628, Aug 3, 2004

Filed:

Jun 11, 2001

Appl. No.:

09/878792

Inventors:

Barbara P. Wallner - Weston MA
Barry Jones - Cambridge MA
Glenn T. Miller - Haverhill MA
Sharlene Adams - Watertown MA

Assignee:

Point Therapeutics, Inc. - Boston MA

International Classification:

A61K 3804

US Classification:

514 19, 514 13, 514 14, 514 15, 514 16, 514 17, 514 18, 514423

Abstract:

Methods and products for stimulating hematopoiesis, preventing low levels of hematopoietic cells and producing increased numbers of hematopoietic and mature blood cells are provided. The methods and products can be used both in vivo and in vitro. The methods involve administering an agent of Formula I: wherein m is an integer between 0 and 10, inclusive; A and A are L-amino acid residues such that the A in each repeating bracketed unit can be the same or a different amino acid residue; the C bonded to B is in the L-configuration; the bonds between A and N, A and C, and between A and N are peptide bonds; and each X and X is, independently, a hydroxyl group or a group capable of being hydrolyzed to a hydroxyl group in aqueous solution at physiological pH. A particularly preferred agent that is useful in practicing the invention is a ValBoroPro.

US Patent:

6835382, Dec 28, 2004

Filed:

Mar 3, 1999

Appl. No.:

09/261894

Inventors:

Robert E. Humphreys - Acton MA
Sharlene Adams - Worcester MA
Minzhen Xu - Northborough MA

Assignee:

University of Massachusetts - Boston MA

International Classification:

A61K 3900

US Classification:

4241851, 514 2, 514 13, 514 14, 514 15, 514 16, 435 71, 435 724, 436501, 436507, 530326, 530327, 530328, 530329

Abstract:

Disclosed is a class of compounds referred to herein as effector compounds. Effector compounds are useful in connection with the modulation of an immune response. Modulation refers to the ability of the effector compounds of the present invention to either enhance (antigen supercharging) or inhibit (immunosuppressant activities) antigen presentation, depending upon the nature of the particular effector compound and the therapeutic context. Effector compounds include peptides, modified peptides and peptidomimetics. Also disclosed are methods for modulating presentation of an MHC class II restricted antigenic peptide to a T cell. Also disclosed are effector compounds demonstrated to act specifically on a human MHC class II allele. Also disclosed is a second class of compounds, referred to herein as immunomodulatory organic compounds. Such compounds are identified by a method which includes the following steps: providing a first complex comprising an MHC class II molecule to which an antigenic peptide has been bound; contacting the first complex with mammalian Ii key peptide LRMKLPKPPKPVSKMR (SEQ ID NO:1) (or modifications thereof including peptidomimetics), thereby forming a second complex; and screening organic molecules for compounds which bind to the second complex but not to the first complex, and which exhibit immunomodulatory activity.

US Patent:

7067489, Jun 27, 2006

Filed:

Jun 28, 2004

Appl. No.:

10/879479

Inventors:

Barbara P. Wallner - Cohasset MA, US
Barry Jones - Cambridge MA, US
Glenn T. Miller - Merrimac MA, US
Sharlene Adams - Waltham MA, US

Assignee:

Point Therapeutics, Inc. - Boston MA

International Classification:

A61K 31/40
A61K 38/04
A61K 38/05

US Classification:

514 13, 514 14, 514 15, 514 16, 514 17, 514 18, 514 19, 514423

Abstract:

Methods and products for stimulating hematopoiesis, preventing low levels of hematopoietic cells and producing increased numbers of hematopoietic and mature blood cells are provided. The methods and products can be used both in vivo and in vitro. The methods involve administering an agent of Formula I.

US Patent:

7205274, Apr 17, 2007

Filed:

Jul 17, 2002

Appl. No.:

10/197000

Inventors:

Robert E. Humphreys - Acton MA, US
Sharlene Adams - Watertown MA, US
Minzhen Xu - Northborough MA, US

Assignee:

Antigen Express, Inc. - Worcester MA

International Classification:

A61K 38/00
A61K 39/385

US Classification:

514 2, 514 12, 514 13, 4241841, 4241851, 4241921, 4241931

Abstract:

The present invention provides an MHC class II antigen presentation enhancing hybrid polypeptide. The hybrid has an N-terminus comprising the mammalian Ii key peptide LRMKLPKPPKPVSKMR (SEQ ID NO: 1) and modifications thereof which retain antigen presentation enhancing activity, a C-terminus comprising an antigenic epitope in the form of a polypeptide or peptidomimetic structure which binds to the antigenic peptide binding site of an MHC class II molecule, and an intervening chemical structure covalently linking the N-terminal and C-terminal components.

US Patent:

7541334, Jun 2, 2009

Filed:

Apr 4, 2007

Appl. No.:

11/732639

Inventors:

Robert E. Humphreys - Acton MA, US
Sharlene Adams - Watertown MA, US
Minzhen Xu - Northborough MA, US

Assignee:

Antigen Express, Inc. - Worcester MA

International Classification:

A61K 38/00
A61K 39/00

US Classification:

514 2, 514 12, 514 13, 4241841, 4241851, 4241921, 4241931

Abstract:

The present invention provides an MHC class II antigen presentation enhancing hybrid polypeptide. The hybrid has an N-terminus comprising the mammalian Ii key peptide LRMKLPKPPKPVSKMR (SEQ ID NO: 1) and modifications thereof which retain antigen presentation enhancing activity, a C-terminus comprising an antigenic epitope in the form of a polypeptide or peptidomimetic structure which binds to the antigenic peptide binding site of an MHC class II molecule, and an intervening chemical structure covalently linking the N-terminal and C-terminal components.

US Patent:

8476409, Jul 2, 2013

Filed:

Apr 19, 2012

Appl. No.:

13/451135

Inventors:

Jason Baum - Needham MA, US
Bryan Johnson - Natick MA, US
Alexey Alexandrovich Lugovskoy - Woburn MA, US
Lihui Xu - Chestnut Hill MA, US
Neeraj Kohli - Brighton MA, US
Jonathan Basil Fitzgerald - Arlington MA, US
Sharlene Adams - Waltham MA, US

Assignee:

Merrimack Pharmaceuticals, Inc. - Cambridge MA

International Classification:

C07K 16/30
C07H 21/04
A61K 39/00

US Classification:

5303873, 5303875, 5303877, 4241331, 4241361, 4241381

Abstract:

Provided are bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3.

US Patent:

20040077601, Apr 22, 2004

Filed:

Jul 9, 2003

Appl. No.:

10/616694

Inventors:

Sharlene Adams - Waltham MA, US
Glenn Miller - Merrimac MA, US
Michael Jesson - Hopedale MA, US
Barry Jones - Cambridge MA, US

Assignee:

Point Therapeutics, Inc. - Boston MA

International Classification:

A61K031/69

US Classification:

514/064000

Abstract:

A method for treating subjects with, inter alia, abnormal cell proliferation or infectious disease. Compositions containing Ile-boroPro compounds are also provided. The invention embraces the use of these compounds alone or in combination with other therapeutic agents.